Sinovac Biotech's Covid-19 vaccine appears to be safe and able to trigger immune responses among children and adolescents, according to preliminary results from early and mid-stage trials, the company said late on Monday.

The preliminary data was from Phase I and II clinical trials involving over 500 people between the ages of three and 17 who received two shots of either medium or low dosage of vaccine, or a placebo...